Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telomir Pharmaceuticals, Inc. ( (TELO) ) has provided an announcement.
On May 19, 2025, Telomir Pharmaceuticals secured $3 million in equity financing through a direct investment by The Bayshore Trust, an entity linked to its largest shareholder. This transaction, executed at an 18% premium to the closing share price, is intended to support the company’s regulatory and development efforts, including the upcoming IND submission for Telomir-1, highlighting insider confidence and strengthening the company’s financial position.
The most recent analyst rating on (TELO) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Telomir Pharmaceuticals, Inc. stock, see the TELO Stock Forecast page.
More about Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing treatments for rare diseases. The company is involved in regulatory and development activities, particularly for its product Telomir-1, which is aimed at addressing rare disease indications.
Average Trading Volume: 169,263
Technical Sentiment Signal: Sell
Current Market Cap: $75.6M
See more insights into TELO stock on TipRanks’ Stock Analysis page.